Subscribe

Elekta AB (publ) (EKTA-B.ST)

SEK47.84 +0.36 (+0.76%)
SE STO Healthcare Medical - Instruments & Supplies
Address Kungstensgatan 18 103 93
Stockholm, SE
CEO Jakob Just-Bomholt
Website elekta.com
IPO 2000-01-03
ISIN SE0000163628

Explore sections of this company profile

Also trades on International Order Book · 0O5H.IL (SEK) Other OTC · EKTAF (USD) Other OTC · EKTAY (USD) Stockholm Stock Exchange · EKTA-B.ST (SEK)
Description

Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK47.84 +0.36 (+0.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.95
Float Shares
318.70M
Free Float %
86.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.66% -11.97% +0.85% -7.49% -7.41% -5.37% +7.83% -32.50% -55.98% -18.33% +1,989.49%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
47.84
DCF (Unlevered) 36.56 -23.6%
DCF (Levered) 58.78 +22.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 33% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 4 0
Hold 3 -1
Sell 4 0
Strong Sell 3 0
Quality scores
Altman Z-Score
1.23
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Instruments & Supplies: +7.9%
    -7.2% Q2'26: -7.6% (vs Q2'25)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    -317.7% Q2'26: -123.8% (vs Q2'25)
  • ✓
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +9.1% ★ Q2'26: +28.2% (vs Q2'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +2.6% Q2'26: -5.0% (vs Q2'25)
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    +3.8% Q2'26: -8.4% (vs Q2'25)
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +0.4% Q2'26: +0.4% (vs Q2'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    4.36× Q2'26: 26.56× (vs Q2'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.96) × ERP
WACC = 74% × Ke + 26% × Kd (5.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 36.56 Current price: 47.84
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Apr 2015
actual 		Apr 2016
actual 		Apr 2017
actual 		Apr 2018
actual 		Apr 2019
actual 		Apr 2020
actual 		Apr 2021
actual 		Apr 2022
actual 		Apr 2023
actual 		Apr 2024
actual 		Apr 2025
actual 		Apr 2026
14 Rev. Ana.
12 EPS Ana. 		Apr 2027
14 Rev. Ana.
10 EPS Ana. 		Apr 2028
13 Rev. Ana.
11 EPS Ana. 		Apr 2029
9 Rev. Ana.
8 EPS Ana. 		Apr 2030
4 Rev. Ana.
5 EPS Ana.
Revenue
10.84B
est: 10.81B (+0.3%)
11.22B
est: 11.42B (-1.7%)
10.70B
est: 10.96B (-2.4%)
11.33B
est: 11.39B (-0.5%)
13.56B
est: 13.18B (+2.8%)
14.60B
est: 14.54B (+0.4%)
13.76B
est: 14.11B (-2.4%)
14.55B
est: 14.35B (+1.4%)
16.87B
est: 16.56B (+1.8%)
18.12B
est: 18.12B (+0.0%)
18.02B
est: 18.06B (-0.2%)
16.92B
16.63B – 17.48B
-6.3% YoY
17.31B
16.90B – 18.63B
+2.3% YoY
18.05B
17.60B – 19.76B
+4.3% YoY
18.68B
18.49B – 18.87B
+3.5% YoY
19.89B
19.41B – 21.60B
+6.5% YoY
EBITDA
1.45B
est: 1.87B (-22.5%)
1.06B
est: 1.97B (-46.1%)
1.20B
est: 1.89B (-36.4%)
2.23B
est: 1.97B (+13.2%)
2.68B
est: 2.28B (+17.8%)
2.94B
est: 2.51B (+17.3%)
3.07B
est: 2.43B (+26.0%)
2.69B
est: 2.48B (+8.6%)
2.57B
est: 2.86B (-10.1%)
3.29B
est: 2.68B (+22.5%)
2.19B
est: 2.67B (-18.1%)
2.51B
2.46B – 2.59B
-6.3% YoY
2.56B
2.50B – 2.76B
+2.3% YoY
2.67B
2.61B – 2.93B
+4.3% YoY
2.77B
2.74B – 2.79B
+3.5% YoY
2.95B
2.87B – 3.20B
+6.5% YoY
EBIT
933.00M
est: 1.09B (-14.7%)
429.00M
est: 1.16B (-62.9%)
549.00M
est: 1.11B (-50.5%)
1.84B
est: 1.15B (+59.9%)
1.74B
est: 1.33B (+30.1%)
1.67B
est: 1.47B (+13.3%)
1.86B
est: 1.43B (+30.4%)
1.65B
est: 1.45B (+13.5%)
1.51B
est: 1.68B (-10.1%)
2.15B
est: 1.44B (+49.6%)
890.00M
est: 1.43B (-37.9%)
1.34B
1.32B – 1.39B
-6.3% YoY
1.37B
1.34B – 1.48B
+2.3% YoY
1.43B
1.40B – 1.57B
+4.3% YoY
1.48B
1.47B – 1.50B
+3.5% YoY
1.58B
1.54B – 1.71B
+6.5% YoY
Net Income
552.00M
est: 681.97M (-19.1%)
137.00M
est: 695.23M (-80.3%)
125.00M
est: 954.80M (-86.9%)
1.10B
est: 1.17B (-6.4%)
1.20B
est: 1.19B (+0.8%)
1.08B
est: 1.17B (-7.3%)
1.25B
est: 1.40B (-10.2%)
1.15B
est: 1.06B (+8.4%)
943.00M
est: 1.12B (-15.9%)
1.30B
est: 1.13B (+14.8%)
237.00M
est: 1.41B (-83.2%)
1.14B
800.66M – 1.48B
-19.0% YoY
1.43B
1.41B – 1.59B
+25.7% YoY
1.61B
1.23B – 1.88B
+12.7% YoY
1.80B
1.09B – 2.05B
+11.8% YoY
2.09B
2.02B – 2.32B
+15.8% YoY
SGA
2.38B
est: 1.84B (+29.7%)
2.36B
est: 1.94B (+21.7%)
2.09B
est: 1.86B (+12.3%)
2.16B
est: 1.94B (+11.3%)
2.34B
est: 2.24B (+4.2%)
2.54B
est: 2.47B (+2.7%)
2.23B
est: 2.40B (-7.0%)
2.53B
est: 2.44B (+3.7%)
3.00B
est: 2.81B (+6.6%)
3.01B
est: 3.18B (-5.4%)
3.06B
est: 3.17B (-3.5%)
2.97B
2.92B – 3.07B
-6.3% YoY
3.04B
2.97B – 3.27B
+2.3% YoY
3.17B
3.09B – 3.47B
+4.3% YoY
3.28B
3.25B – 3.31B
+3.5% YoY
3.49B
3.41B – 3.79B
+6.5% YoY
EPS
1.45
est: 1.78 (-18.7%)
0.36
est: 1.82 (-80.2%)
0.33
est: 2.50 (-86.8%)
2.88
est: 3.07 (-6.2%)
3.14
est: 3.11 (+1.0%)
2.84
est: 3.06 (-7.2%)
3.28
est: 3.65 (-10.2%)
3.02
est: 2.78 (+8.4%)
2.47
est: 2.95 (-16.2%)
3.41
est: 2.97 (+14.9%)
0.62
est: 3.53 (-82.4%)
3.39
2.09 – 3.86
-3.9% YoY
3.89
3.67 – 4.15
+14.6% YoY
4.27
3.21 – 4.91
+9.8% YoY
4.75
2.85 – 5.34
+11.4% YoY
5.45
5.27 – 6.05
+14.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 4/5 1/5 1/5 1/5 1/5 2/5
2026-05-28 C 2/5 4/5 1/5 1/5 1/5 1/5 2/5
2026-05-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-26 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-25 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-22 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-21 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-19 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-18 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-15 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-13 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-12 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-11 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-06 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-05 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-04 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.94B
OE per share TTM
5.07
Owner's Yield
9.43%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 76 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 VanEck Morningstar International Moat ETF MOTI 2.27% 1.60M 0.58%
2 VanEck Morningstar Global Wide Moat ETF MOTG 1.72% 300.3K 0.52%
3 VanEck Morningstar Global Wide Moat UCITS ETF GOAT.L 1.71% 2.91M 0.52%
4 Global X Robo Global Robotics and Automation ETF ROBO.AX 0.95% 2.04M 0.69%
5 iShares OMX Stockholm Capped UCITS ETF OM3X.DE 0.22% 469.1K 0.10%
6 iShares Healthcare Innovation UCITS ETF HEAL.L 0.22% 2.50M 0.40%
7 iShares Ageing Population UCITS ETF AGED.L 0.17% 1.48M 0.40%
8 iShares MSCI Europe Small-Cap ETF IEUS 0.13% 219.6K 0.41%
9 Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L 0.12% 4.04M 0.30%
10 FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD 0.12% 771.5K 0.41%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
95.6K
Shares Outstanding
367.10M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jonas Bolander Chief Legal Officer 8M male
Laurent Leksell Founder & Chairman 2M —
Caroline Leksell Cooke Senior Vice President & Head of Neuro Solutions 149.0K female
Hilma Nordquist Global Sustainability Director — —
Jakob Just-Bomholt Chief Executive Officer & President — male
John Lapré Chief Business Line Officer — male
Klara Eiritz Chief Financial Officer — female
Mattias Thorsson Vice President and Head of Corporate Communications & Public Affairs — male
Peter Nyquist Head of Investor Relations — male
Christina Raaschou Chief People Officer — female
Christopher Busch Chief Product & Technology Officer — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies